Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Holding Corp.

NNASDAQ:TNXP
2.88
USD
-0.13
(-4.32%)
-11.95EPS
186.52MMarket Cap
Mar 15Next Earn
Tonix Pharmaceuticals Holding Corp.
NASDAQ:TNXP
(Nasdaq Stock Market)

Recent

price

2.88

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
USD
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
980.19
13.71
1.54
2.84
Revenue per Share
-1,964,470
-578,352.17
-945,000
-10,884,000
-27,616,000
-24,027,000
-6,473,666.67
-1,760,250
-587,100
-2,391,692.31
-161,130.84
-119,080
-65,440.65
-14,720.25
-176.6
-14.57
-11.95
Basic EPS, GAAP
-1,267,620
-440,050.33
-574,900
-8,532,000
-23,159,000
-21,383,000
-6,229,833.33
-1,594,416.67
-479,540
-2,053,846.15
-177,975.08
-143,050.32
-81,858.9
-13,867.26
-82.9
-12.13
-11.23
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
724,384.62
273,046.73
282,215.48
54,193.57
5,761.04
31.82
19.17
10.42
Book Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
715,153.85
272,672.9
282,060.65
54,162.18
5,176.45
31.79
19.16
10.42
Tangible Book Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
9
15
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
8
10
13
43
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-1,523.94
-744.5
-936.07
-433.15
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
4
3
2
2
Depreciation Expense
-2
-3
-9
-11
-28
-48
-39
-21
-26
-29
-50
-92
-110
-117
-130
-124
-181
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-1,501.78
-1,288.25
-946.22
-420.45
Profit Margin (%)
- -
-1
1
6
36
40
25
24
23
9
78
167
113
29
101
198
150
Working Capital
- -
2
- -
- -
- -
- -
- -
- -
- -
- -
1
- -
- -
7
5
1
1
LT Debt
- -
-2
1
7
36
40
25
25
24
9
88
219
207
106
140
245
199
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
-291.37
-129.64
-125.87
-118.38
-84.53
-121.6
-187.97
-106.57
-60.25
-54.88
-74.61
-106.12
-64.48
-84.06
Return on Common Equity (%)

Capital Structure

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
1
1
1
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
14
17
19
Market Capitalization
195
214
187

Working Capital

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
207
203
192
Cash, Cash Equivalents & STI
185
176
163
Accounts Receivable, Net
9
12
15
Inventories
5
6
4
Total Current Liabilities
30
31
42
Payables & Accruals
18
19
29
ST Debt
- -
- -
- -
Deferred Revenue
4
4
5

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
92.98%
40.62%
75.66%
Free Cash Flow
21.5%
25.15%
69.08%
Net Income, GAAP
15.97%
23%
-4.63%
Sales/Revenue/Turnover
- -
- -
29.85%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
2
2
3
3
10
2025
2
2
3
5
13
2026
7
14
17
- -
- -

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-535.72
-1,920.85
-22.68
-9.77
-176.6
2025
-2.84
-3.86
-3.59
-3.98
-14.57
2026
-2.93
-2.44
-2.89
- -
- -

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Business
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) is a clinical-stage biopharmaceutical company focused on developing novel therapies for central nervous system disorders, immunology, and infectious diseases. The company offers a pipeline of product candidates including TNX-102 SL, a non-opioid sublingual tablet for fibromyalgia and acute stress reaction post-traumatic stress disorder; TNX-1300, an IV formulation of cocaine for rapid-onset cocaine intoxication; TNX-1500, a monoclonal antibody targeting CD40 ligand for organ transplant rejection and autoimmune conditions; TNX-2900, a nasal spray oxytocin antagonist for Prader-Willi syndrome; and TNX-801, a live virus vaccine for smallpox and mpox; along with TNX-1800, a live virus vaccine for SARS-CoV-2. These products target unmet medical needs in pain management, neurology, vaccinology, and biologics, serving patients through clinical development and potential commercialization. Founded in 2007 and headquartered in Chatham, New Jersey, Tonix Pharmaceuticals operates primarily in the United States with clinical trials conducted globally. In recent developments, the company reported positive Phase 3 data for TNX-102 SL in fibromyalgia during 2024, advancing toward an NDA filing expected in early 2025; expanded its infectious disease portfolio through preclinical progress on TNX-801 and TNX-1800 amid mpox outbreaks; and strengthened its balance sheet via a public offering in late 2024, supporting ongoing CNS and immunology programs. Additionally, Tonix entered a strategic collaboration with Makana Therapeutics in 2024 to co-develop TNX-1500 for transplant indications, marking a key alliance in biologics.

Company News

  • Tonix Pharmaceuticals' TONMYA Sales Jump 37% as Insurance Coverage Expands

  • Tonix Pharmaceuticals Holding Corp. (TNXP) Q3 2026 Earnings Call Transcript

  • What Tonix Pharmaceuticals (TNXP) Said on Its Q3 Earnings Call

  • Tonix Pharmaceuticals Reports Third Quarter 2026 Financial Results and Operational Highlights

  • Tonix Pharmaceuticals to Present at Guggenheim's 3rd Annual Healthcare Innovation Conference

  • Tonix Pharmaceuticals Appoints George Lederman, Ph.D., as Executive Vice President of Strategy and Transformation

  • Tonix Pharmaceuticals Presented an Analysis of Phase 3 Data Demonstrating TONMYA® Improved Physical Symptoms and Functional Ability of Patients with Fibromyalgia at the IASP 2026 World Congress on Pain

  • Tonix Pharmaceuticals to Report Third Quarter 2026 Financial Results on November 9, 2026

  • A New Fibromyalgia Drug Deal Reaches 21 Million More Medicare Lives. Her Own Plan Could Still Decide What She Pays

  • Tonix Pharmaceuticals to Present an Analysis of Phase 3 Data on TONMYA® at the IASP 2026 World Congress on Pain

  • Tonix Pharmaceuticals Announces Presentations at World Vaccine Congress Europe 2026

  • Analyzing Tonix Pharmaceuticals (NASDAQ:TNXP) and WAVE Life Sciences (NASDAQ:WVE)

  • Tonix Pharmaceuticals Announces Second Major Managed Medicare Payer Agreement for TONMYA®

  • Tonix Pharmaceuticals (NASDAQ:TNXP) and Voyager Therapeutics (NASDAQ:VYGR) Critical Review

  • Tonix Pharmaceuticals Targets TONMYA Growth as Lyme Prevention Trial Nears

  • Tonix Pharmaceuticals Promotes Thomas Englese, MBA, to Chief Commercial Officer

  • Tonix Pharmaceuticals to Participate in Cantor's 2026 Global Healthcare Conference

  • Tonix Pharmaceuticals Highlights TONMYA Sales Surge, Lyme and Depression Pipeline

  • Tonix Pharmaceuticals Q2 Earnings Call Highlights

  • Tonix Pharmaceuticals Holding Corp. (TNXP) Q2 2026 Earnings Call Transcript